Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 10/20 | 0.48 |
| ▸ | MAOB | P27338 | 6/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5266396 | 0.81 | KDM4E (0.56) | GAALMNAKDM4EALDH1A1CYP19A1 | |
| SCHEMBL22319275 | 0.80 | GAA (0.52) | GAALMNAKDM4EALDH1A1CYP19A1 | |
| SCHEMBL22319274 | 0.80 | GAA (0.52) | GAALMNAKDM4EALDH1A1CYP19A1 | |
| SCHEMBL30375827 | 0.80 | GAA (0.52) | GAALMNAKDM4EALDH1A1CYP19A1 | |
| SCHEMBL10163625 | 0.79 | LMNA (0.51) | GAALMNAKDM4EALDH1A1CYP19A1 | |
| SCHEMBL10132576 | 0.78 | GAA (0.53) | GAALMNAKDM4EALDH1A1CYP19A1 | |
| SCHEMBL10069796 | 0.78 | MAP2K3 (0.59) | GAALMNAKDM4EALDH1A1CYP19A1 | |
| SCHEMBL318173 | 0.77 | LMNA (0.47) | GAALMNAKDM4EALDH1A1CYP19A1 | |
| SCHEMBL10108843 | 0.77 | LMNA (0.47) | GAALMNAKDM4EALDH1A1CYP19A1 | |
| SCHEMBL318058 | 0.77 | LMNA (0.47) | GAALMNAKDM4EALDH1A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096520-B2 | Tricyclic ideno-pyrrole derivatives as serotonin receptor modulators | ABT HOLDING COMPANY (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140206739-A1 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | ABT HOLDING COMPANY (US) | 2014-07-24 | — | — | US | disclosed |
| US-8716324-B2 | Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators | ATHERSYS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20120252859-A1 | Tricyclic Indeno-Pyrrole Derivatives as Serotonin Receptor Modulators | ATHERSYS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-8232311-B2 | Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators | ATHERSYS, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110172283-A1 | Tricyclic Indeno-Pyrrole Derivatives as Serotonin Receptor Modulators | BENNANI YOUSSEF L | 2011-07-14 | — | — | US | disclosed |
| US-7935830-B2 | Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators | ATHERSYS, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090239925-A1 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | ATHERSYS, INC. | 2009-09-24 | — | — | US | disclosed |
| EP-1841738-A2 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | Athersys, Inc. (US) | 2007-10-10 | — | — | EP | disclosed |
| WO-2007081299-A2 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | ATHERSYS, INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| US-20060025601-A1 | Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators | ATHERSYS, INC. | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252859-A1 | Tricyclic Indeno-Pyrrole Derivatives as Serotonin Receptor Modulators | HTR5A, HTR3E, HTR1E | GAA 3221/4885LMNA 3856/4885KDM4E 1149/4885 |
| US-20110172283-A1 | Tricyclic Indeno-Pyrrole Derivatives as Serotonin Receptor Modulators | HTR5A, HTR3E, HTR1E | GAA 3221/4885LMNA 3856/4885KDM4E 1149/4885 |
| US-20060025601-A1 | Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators | HTR5A, HTR3E, HTR1E | GAA 3221/4885LMNA 3856/4885KDM4E 1149/4885 |
| US-20090239925-A1 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | HTR5A, HTR3E, HTR1E | GAA 3221/4885LMNA 3856/4885KDM4E 1149/4885 |
| US-20140206739-A1 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | HTR5A, HTR3E, HTR1E | GAA 3221/4885LMNA 3856/4885KDM4E 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.